# US 2025/0084442 A1 · Methods of biallelic modification

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084442 A1
- Document ID: US20250084442A1
- Status: Published application
- Kind: A1
- Application number: 18/885,348
- Filed: 2024-09-13
- Published: 2025-03-13
- Earliest claimed: 2023-09-13
- Assignees: Virginia Tech Intellectual Properties, Inc.
- Applicants: Virginia Tech Intellectual Properties, Inc.
- Inventors: Fernando Biase
- Web page: https://patentgrep.com/patent/US20250084442A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/907: {in mammalian cells}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- A01K 2217/075: inducing loss of function, i.e. knock out
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Described herein are methods and techniques for biallelic modification of DNA.

## Claims

### Claim 1

A method of biallelic DNA modification comprising:
modifying a target DNA using a DNA modification agent; and
knocking down target RNA using an RNA modification agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the DNA modification agent is a CRISPR-Cas system, a TALEN, a Zinc Finger Nuclease, an Omega System, a transposase, a recombinase, a recombinase-based system, a non-LTR retrotransposon, or a meganuclease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the DNA modification agent is a Type II CRISPR-Cas system.

### Claim 4 (depends on 3)

The method of claim 3, wherein the DNA modification agent is a CRISPR-Cas9 system.

### Claim 5 (depends on 4)

The method of claim 4, wherein the DNA modification agent is a CRISPR-Cas9D1-A system.

### Claim 6 (depends on 1)

The method of claim 1, wherein the RNA modification agent is a CRISPR-Cas system or RNAi.

### Claim 7 (depends on 6)

The method of claim 6, wherein the RNA modification agent is a Type VI CRISPR-Cas system.

### Claim 8 (depends on 7)

The method of claim 7, wherein the RNA modification agent is a CRISPR-Cas13 system.

### Claim 9 (depends on 8)

The method of claim 8, wherein the RNA modification agent is a CRISPR-Cas13a system.

### Claim 10 (depends on 1)

The method of claim 1, wherein modifying, knocking down, or both occurs in vivo or in vitro.

### Claim 11 (depends on 10)

The method of claim 10, wherein modifying, knocking down, or both occurs in a cell.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cell is a zygote.

### Claim 13 (depends on 11)

The method of claim 11, wherein the cell is a non-human animal cell.

### Claim 14 (depends on 13)

The method of claim 13, wherein the non-human animal is a bovine, porcine, ovine, canine, feline, or equine.

### Claim 15 (depends on 10)

The method of claim 10, wherein delivery of the DNA modifying agent and/or RNA modifying agent occurs via electroporation.

### Claim 16 (depends on 1)

A modified DNA produced by the method of claim 1.

### Claim 17 (depends on 1)

A cell comprising modified DNA produced by the method of claim 1.

### Claim 18 (depends on 17)

The cell of claim 17, wherein the cell is a zygote.

### Claim 19 (depends on 17)

The cell of claim 17, wherein the cell is a non-human animal cell.

### Claim 20 (depends on 19)

The cell of any one of claim 19, wherein the non-human animal is a bovine, porcine, ovine, canine, feline, or equine.
